申请人:"NTZ LAB" LTD.
公开号:US20150353504A1
公开(公告)日:2015-12-10
Substituted indazole or imidazole derivatives of formula I as in vitro selective and reversible MAO-B inhibitors and for use in the prevention and treatment of meurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and dementia
公式I中的替代吲唑或咪唑衍生物可作为体外选择性和可逆的MAO-B抑制剂,并用于预防和治疗神经退行性疾病,如帕金森病、阿尔茨海默病和痴呆症。